Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2019-01-31 Investor Presentation
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics présente son plan d'actions 2019
Investor Presentation Classification · 98% confidence The document is titled "Quantum Genomics présente son plan d'actions 2019" (Quantum Genomics presents its 2019 action plan). It details strategic plans, clinical trial updates (NEW-HOPE Phase IIb results, planning for Phase III design, launching Quorum Phase IIb), expected timelines for results (Q2 2019), and management commentary on partnership discussions. This content strongly aligns with an Investor Presentation (IP), which typically outlines strategy, pipeline progress, and future outlook for investors, rather than being a formal regulatory filing like a 10-K or a brief earnings release (ER). It is too detailed for an ER and too forward-looking/strategic for a standard Interim Report (IR).
2019-01-31 French
Quantum Genomics Appoints Steering Committee for its Phase III Pivotal Trial in Resistant Hypertension
Regulatory Filings Classification · 94% confidence The document is a press release announcing the appointment of a steering committee for a Phase III clinical trial. It contains company updates, scientific information, and an upcoming events calendar, including the date for the '2018 Annual Results' and 'General Meeting of Shareholders'. This format is typical of a general corporate announcement or news release that does not fit the strict definitions of a 10-K, ER, or IR. Since it is a specific corporate update (appointment of experts for a trial) and not a general regulatory filing fallback (RNS), nor a specific report like an ER or IR, it most closely aligns with a general corporate communication. Given the options, and since it is not a formal financial report, management discussion, or specific regulatory filing like DIRS or DIV, the most appropriate general category for a significant, non-financial-results-focused corporate announcement is often RNS (Regulatory Filings) if no better fit exists, or potentially a general Investor Relations communication. However, looking closely at the definitions, this is a specific operational/scientific update. It is not a DEF 14A (Remuneration), DIRS (Director Dealing), or DIV (Dividend). It is not an ER (Earnings Release) or IR (Interim Report). Since it is a specific announcement about company operations (clinical trial planning) and not a formal report itself, and it doesn't fit MANG (Board change), TAR (M&A), or CAP (Financing), the best fit among the provided codes for a significant, non-standard corporate announcement is RNS (Regulatory Filings) as a general catch-all for important news releases that aren't explicitly defined elsewhere, although it is a very specific type of news release. Given the content is purely operational/scientific news, RNS is the most suitable fallback.
2019-01-17 English
Half-yearly report on the liquidity contract at 31 December 2018 (french only)
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité au 31 décembre 2018" (Semi-annual balance sheet of the liquidity contract as of December 31, 2018). It details the assets (cash and shares) held under a liquidity contract with an investment firm (Invest Securities) for Quantum Genomics. This type of filing, reporting on the status of a liquidity agreement, is a specific regulatory or market-related disclosure. It is not a full Annual Report (10-K), an Interim Report (IR), an Earnings Release (ER), or a standard management discussion (MDA). It relates to the company's financial arrangements and market operations. Given the specific nature of reporting on liquidity contracts, which often falls under market surveillance or specific regulatory requirements, and since there isn't a dedicated code for 'Liquidity Contract Report', the most appropriate general category for specific, non-standard regulatory disclosures is 'Regulatory Filings' (RNS). It is a specific report, not an announcement of a report, so RPA is less suitable than RNS for this specific content type.
2019-01-15 English
Information relating to the total number of voting rights forming the share capital
Share Issue/Capital Change Classification · 95% confidence The document explicitly details the 'Total number of shares forming the share capital' and 'Total number of voting rights' as of a specific date (31/12/2018), referencing French commercial code and AMF regulations. This type of mandatory disclosure regarding the structure of the share capital and voting power is typically associated with regulatory reporting concerning capital changes or shareholder rights. While it is not a full financial report (10-K or IR), it directly relates to the company's capital structure and voting rights. The closest specific category is 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it quantifies the voting rights. It is a specific regulatory disclosure, not a general announcement (RPA/RNS) or a management/board change (MANG).
2019-01-14 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital" (Information relative to the total number of voting rights and shares comprising the capital) and explicitly references the French Commercial Code (Code de commerce) and AMF regulations. It provides a table detailing the total number of shares and voting rights as of a specific date (31/12/2018), including details on new shares issued. This type of mandatory disclosure regarding the capital structure and voting rights is a specific regulatory filing in France. While it relates to capital structure, it is not a general financing announcement (CAP) or a share issue announcement (SHA) in the context of a primary offering or buyback, but rather a periodic statement of the total outstanding capital and voting power. This fits best under the general regulatory filing category, RNS, as it is a specific regulatory disclosure that doesn't map perfectly to the other specialized codes like 10-K, ER, or DIV. Given the context of mandatory disclosure of voting rights, it is a regulatory filing.
2019-01-14 French
Bilan semestriel du contrat de liquidité au 31 décembre 2018
Earnings Release Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité au 31 décembre 2018" (Semi-annual balance sheet of the liquidity contract as of December 31, 2018). It details the assets (cash and shares) held under a liquidity contract with an investment firm (Invest Securities) for Quantum Genomics. This type of filing, reporting on the status of a liquidity agreement, is a specific regulatory or market-related disclosure. It is not a full Annual Report (10-K), an Interim Report (IR), an Earnings Release (ER), or a standard management discussion (MDA). It relates to the company's financial arrangements and market operations. Given the specific nature of reporting on liquidity contracts, which often falls under market surveillance or specific regulatory requirements, and since there isn't a dedicated code for 'Liquidity Contract Report', the most appropriate general category for specific, non-standard regulatory disclosures is 'Regulatory Filings' (RNS). It is a specific report, not an announcement of a report, so RPA is less suitable than RNS for this specific content type. H2 2018
2019-01-03 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.